Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation
Status:
Unknown status
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The investigators have conducted a prospective, double-blind, randomized study to assess the
comparative safety and efficacy of two different ablation strategies, PVI plus linear lesions
(LL) plus botulinum toxin injection versus PVI plus linear lesions (LL), in patients with
persistent or longstanding persistent AF. Results were assessed with the use of an implanted
monitoring device (IMD).
Phase:
Phase 2
Details
Lead Sponsor:
Meshalkin Research Institute of Pathology of Circulation